500 Shares in Eli Lilly and Company $LLY Bought by Independent Family Office LLC

Independent Family Office LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 500 shares of the company’s stock, valued at approximately $390,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. PNC Financial Services Group Inc. raised its stake in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the last quarter. Wellington Management Group LLP grew its holdings in Eli Lilly and Company by 0.6% during the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after purchasing an additional 81,587 shares during the last quarter. Laurel Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Finally, Norges Bank acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $8,827,714,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.7%

NYSE LLY opened at $1,074.94 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a 50-day simple moving average of $889.37 and a 200 day simple moving average of $799.23. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The stock has a market cap of $1.02 trillion, a PE ratio of 70.26, a PEG ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LLY. Daiwa Capital Markets raised their target price on shares of Eli Lilly and Company from $700.00 to $940.00 in a research note on Monday, November 10th. UBS Group upped their price target on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a report on Friday, November 7th. Sanford C. Bernstein raised their price target on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a research report on Monday. Scotiabank assumed coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price objective for the company. Finally, Leerink Partners upgraded Eli Lilly and Company from a “market perform” rating to an “outperform” rating and increased their target price for the company from $886.00 to $1,104.00 in a research note on Monday, November 10th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,047.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.